暂无数据
暂无内容
暂无数据
暂无数据
暂无数据
ClearPoint Neuro将在巴尔的摩举行的美国基因与细胞疗法学会第27届年会上展示新的研究和展览
加利福尼亚州索拉纳海滩,2024年5月2日(GLOBE NEWSWIRE)——ClearPoint Neuro, Inc.(纳斯达克股票代码:CLPT)(“公司”),一家支持设备、细胞和基因疗法的全球公司,提供精确的导航
GlobeNewswire05/02 16:05 (美东)
临床激光热疗注意事项美国食品药品管理局批准了 ClearPoint 的 Prism 骨锚配件
临床激光热系统(CLS-B.ST)合作伙伴ClearPoint Neuro的棱镜骨锚配件获得了美国食品药品监督管理局的510(k)批准。预计该批准将有所帮助
MT Newswires04/30 09:17 (美东)
ClearPoint 获得 FDA 神经外科设备的许可
ClearPoint Neuro(CLPT)周一表示,其棱镜骨锚配件已获得美国食品药品监督管理局的510(k)批准。Prism 骨锚配件专为 s 使用而设计
MT Newswires04/29 15:23 (美东)
快讯 | Clearpoint Neuro Inc——计划在第二季度按计划开始限量上市,并于2024年下半年全面上市
Reuters04/29 08:10 (美东)
快讯 | ClearPoint Neuro 的 Prism 骨锚配件获得了 FDA 的批准
Benzinga04/29 08:03 (美东)
快讯 | Clearpoint Neuro 宣布 FDA 批准 Prism 骨锚配件
Reuters04/29 08:00 (美东)
Jaguar8 : I CONCUR!
Trytosaveabit楼主 Jaguar8: How did I know you would! Oh yeah that’s right! You have witnessed first hand how the advancement of the super rare and extremely hard to treat weight loss drugs move The price on the very slightest of good PR! Again because of how hard it is to treat? Even a tiny bit of good news is met with powerful price movements! Hehehe
Jaguar8 Trytosaveabit楼主: Oh yes even on just preclinical stage, the overweight study flies! Its obsession with overweight studies tied with obsession with obesity -inducing lifestyle and I’m not saying lifestyle is the only cause of obesity but it is the MAJOR factor.
Trytosaveabit楼主 : Clearpoint Neuro Inc - Plan to Begin Limited Market Release on Schedule in Q2, With a Full Market Release in Second Half of 2024
暂无数据
暂无数据